机构：[1]Department of Medical Oncology, Yidu Central Hospital of Weifang, Weifang, Shandong Province, China[2]Department of Urology, Shouguang Hospital of Traditional Chinese Medicine, Shouguang, Shandong Province, China[3]Guangdong TCRCure Biopharma Technology Co., Ltd, Guangzhou, China[4]Department of Biochemistry, School of Life Sciences, University of Sussex, Brighton, UK[5]Division of Cancer, Department of Surgery and Cancer, Imperial College London, London, UK[6]Department of Biomedical Sciences, Anglia Ruskin University, Cambridge, UK[7]Department of Medical Oncology, Shouguang Hospital of Traditional Chinese Medicine, Shouguang, Shandong Province, China[8]Department of Respiratory Disease, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang Province, China
This study was supported by a grant from Medical Science
Research Foundation of Health Bureau of Zhejiang Province (Grant
number: 2022KY545) and a grant from the Zhejiang Traditional Chinese
Medicine Administration (Grant number: 2022ZA021).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类|4 区医学
小类|4 区生化与分子生物学4 区生物工程与应用微生物
最新[2025]版：
大类|4 区生物学
小类|4 区生化与分子生物学4 区生物工程与应用微生物
第一作者：
第一作者机构：[1]Department of Medical Oncology, Yidu Central Hospital of Weifang, Weifang, Shandong Province, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Wang Peng,Wang Zhiqiang,Lin Yanke,et al.Development of a Novel Pyroptosis-Associated lncRNA Biomarker Signature in Lung Adenocarcinoma[J].Molecular biotechnology.2023,doi:10.1007/s12033-023-00757-4.
APA：
Wang Peng,Wang Zhiqiang,Lin Yanke,Castellano Leandro,Stebbing Justin...&Peng Ling.(2023).Development of a Novel Pyroptosis-Associated lncRNA Biomarker Signature in Lung Adenocarcinoma.Molecular biotechnology,,
MLA：
Wang Peng,et al."Development of a Novel Pyroptosis-Associated lncRNA Biomarker Signature in Lung Adenocarcinoma".Molecular biotechnology .(2023)
